This report examines the role of biosimilars in improving access to biologic medicines while supporting sustainable healthcare systems. It analyzes global adoption trends, regulatory pathways, pricing dynamics, and payer strategies, highlighting wide variation across regions. While Europe has seen strong uptake driven by tendering and policy support, the U.S. market faces slower adoption due to patent litigation, contracting practices, and provider incentives. The report emphasizes that biosimilars deliver savings primarily through competition rather than dramatic price cuts. It concludes that coordinated policy action, education, and aligned incentives are required to unlock the full value of biosimilars for patients and health systems.

Join for free to read